Abaloparatide (Tymlos) vs Orforglipron (LY-3502970)
Updated October 27, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of Abaloparatide (Tymlos) and Orforglipron (LY-3502970) (also searched as Orforglipron (LY-3502970) vs Abaloparatide (Tymlos)) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
Abaloparatide (Tymlos) centers on healing, while Orforglipron (LY-3502970) leans toward metabolic. On indexed research, Orforglipron (LY-3502970) is ahead (Abaloparatide (Tymlos): 35 studies, Human clinical; Orforglipron (LY-3502970): 36, Human clinical). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •Abaloparatide (Tymlos) is strongest for healing; Orforglipron (LY-3502970) for metabolic.
- •Evidence: Abaloparatide (Tymlos) Human clinical (35 studies) vs Orforglipron (LY-3502970) Human clinical (36).
- •Check the FDA-approval status chips above before assuming a legal use pathway.
Effect profiles, overlaid
At a glance
PTH1R Activation | Osteoporosis Treatment
GLP-1 Agonist | Type 2 Diabetes and Obesity
Abaloparatide (Tymlos) vs Orforglipron (LY-3502970): side-by-side
| Metric | Abaloparatide (Tymlos) | Orforglipron (LY-3502970) |
|---|---|---|
| Class | Healing | Metabolic |
| Regulatory status | FDA-approved | FDA-approved |
| Evidence grade | Human clinical | Human clinical |
| Studies indexed | 35 | 36 |
| Research level | FDA Approved | FDA Approved |
| Strongest effect | Healing & recovery | Metabolic & appetite |
| Healing & recovery | 4.0▲ | 2.0 |
| Muscle & body comp | 1.0▲ | 1.0▲ |
| Metabolic & appetite | 2.0 | 5.0▲ |
| Neuro & mood | 0.0 | 2.0▲ |
| Sleep & circadian | 0.0 | 2.0▲ |
| Inflammation & immune | 1.0 | 3.0▲ |
| Skin & aesthetics | 0.0 | 3.0▲ |
▲ marks the higher AI-assigned effect score (0–5, describing where the literature concentrates — not clinical efficacy).
Mechanism & pharmacokinetics
| Property | Abaloparatide (Tymlos) | Orforglipron (LY-3502970) |
|---|---|---|
| Mechanism | PTH1R agonist | GLP-1 receptor agonist |
| Route | Subcutaneous injection | Oral |
| Half-life | ~30 min | — |
| Time to peak | 4 hours | — |
| Duration of action | 24 hours | — |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is Abaloparatide (Tymlos)?
Abaloparatide (Tymlos) is a synthetic PTHrP analog and FDA-approved anabolic agent for osteoporosis, building bone via selective PTH1R activation.
Full Abaloparatide (Tymlos) profile, mechanism & studies →What is Orforglipron (LY-3502970)?
Orforglipron (LY-3502970) is an investigational oral small-molecule GLP-1 receptor agonist studied for type 2 diabetes and obesity, offering pill-based dosing without injection.
Full Orforglipron (LY-3502970) profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | Abaloparatide (Tymlos) | 4.0/5 effect signal |
| Muscle | Even | Both ~1.0/5 |
| Metabolic | Orforglipron (LY-3502970) | 5.0/5 effect signal |
| Neuro | Orforglipron (LY-3502970) | 2.0/5 effect signal |
| Sleep | Orforglipron (LY-3502970) | 2.0/5 effect signal |
| Inflammation | Orforglipron (LY-3502970) | 3.0/5 effect signal |
| Skin | Orforglipron (LY-3502970) | 3.0/5 effect signal |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack Abaloparatide (Tymlos) and Orforglipron (LY-3502970)?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because at least one is a research-use compound, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
Abaloparatide (Tymlos) vs Orforglipron (LY-3502970): side effects
No community-reported effects logged yet.
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
Abaloparatide (Tymlos) has 35 approved studies indexed (Human clinical), and Orforglipron (LY-3502970) has 36 (Human clinical). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is Abaloparatide (Tymlos) or Orforglipron (LY-3502970) better?
It depends on your goal. Abaloparatide (Tymlos) is strongest for healing; Orforglipron (LY-3502970) for metabolic. Orforglipron (LY-3502970) has more indexed studies (36). See the goal-by-goal breakdown above.
Is Abaloparatide (Tymlos) or Orforglipron (LY-3502970) better for weight loss?
Orforglipron (LY-3502970) shows the stronger metabolic & appetite profile (5.0/5) in the AI-assigned effect profile — though weight-loss outcomes depend on the individual and the evidence base.
Is Abaloparatide (Tymlos) or Orforglipron (LY-3502970) better for muscle?
Both land close on the muscle & body-composition axis.
Which has more research, Abaloparatide (Tymlos) or Orforglipron (LY-3502970)?
Abaloparatide (Tymlos) has 35 approved studies indexed (Human clinical); Orforglipron (LY-3502970) has 36 (Human clinical). Higher counts mean more to read, not proven superiority.
Can you stack Abaloparatide (Tymlos) and Orforglipron (LY-3502970)?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of Abaloparatide (Tymlos) vs Orforglipron (LY-3502970)?
Abaloparatide (Tymlos): no community-reported effects logged yet. Orforglipron (LY-3502970): none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is Abaloparatide (Tymlos) or Orforglipron (LY-3502970) FDA-approved?
Abaloparatide (Tymlos) is FDA-approved. Orforglipron (LY-3502970) is FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is Orforglipron (LY-3502970) better than Abaloparatide (Tymlos)?
For metabolic, Orforglipron (LY-3502970) has the edge; for healing, Abaloparatide (Tymlos) does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
Approval status varies (see the chips at the top). FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed October 27, 2026.